Last reviewed · How we verify
NCT06651853
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Phase 2 trial testing Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab in Diffuse Large B-cell Lymphoma in 22 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | The First Affiliated Hospital of Xiamen University |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 22 |
| Start date | 21 October 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 30 July 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab — full drug profile →
Conditions studied
- Diffuse Large B-cell Lymphoma — all drugs for Diffuse Large B-cell Lymphoma →
- Relapsed and Refractory — all drugs for Relapsed and Refractory →
Sponsor
The First Affiliated Hospital of Xiamen University
Who can join
18 and older, any sex, with Diffuse Large B-cell Lymphoma or Relapsed and Refractory. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To prospectively evaluate the efficacy and safety of large fraction radiation therapy combined with granulocyte-macrophage colony-stimulating factor, lenalidomide, and glofitamab monoclonal antibody in the treatment of refractory relapsed diffuse large B-cell lymphoma patients
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy.
Schipani M, Bellia M, Sella C, Dondolin R, et al · · 2025 · cited 1× · PMID 41097784 · DOI 10.3390/cancers17193258 -
Molecular Mechanisms of Resistance to Bispecific Antibodies in Diffuse Large B-Cell Lymphoma.
Maher N, Al Deeban B, Diop NM, Assaf J, et al · · 2026 · PMID 42121895 · DOI 10.3390/cells15090794
Verify or expand the search:
- PubMed search for NCT06651853
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diffuse Large B-cell Lymphoma
Currently open trials in the same condition.
- NCT06977711 — Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large · Phase 1 · recruiting
- NCT06846463 — Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+ · Phase 2 · recruiting
- NCT06870487 — A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers · Phase 1 · active not recruiting
- NCT06503263 — Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL · Phase 2 · recruiting
- NCT06395103 — Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumo · Phase 1, PHASE2 · recruiting
Other The First Affiliated Hospital of Xiamen University trials
Trials by the same sponsor.
- NCT06875063 — GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL · Phase 1 · recruiting
- NCT07486492 — Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer · EARLY_PHASE1 · not yet recruiting
- NCT07458906 — DLL3-Targeted PET/CT in Neuroendocrine Carcinoma · NA · recruiting
- NCT07137052 — Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinomar · not yet recruiting
- NCT07189884 — Pyrotinib Maleate Tablets in Combination With Dalpiciclib Isethionate Tablets and Standard Endocrine Therapy · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06651853 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Xiamen University
- Last refreshed: 23 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06651853.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing